Juvaris BioTherapeutics

Juvaris BioTherapeutics is developing adjuvant vaccines and immunotherapies for the treatment of infectious diseases and cancer. The company's platform technology induces deep immune stimulation through cationic lipid-DNA (non-coding) complexes (CLDC). The company’s lead candidate, JVRS-100, stimulates adaptive and innate immune responses at levels many times higher than other similar drugs. JVRS-100 is currently in clinical development as a vaccine adjuvant and immunotherapy agent.